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background:  A previous non-randomized comparison between Absorb and Xience has suggested a reduction of angina with Absorb.
methods:  ABSORB II randomly compared Absorb with Xience in 501 pts (randomization ratio 2:1). New or worsening (NW) angina after 
index procedure as diagnosed by the site was captured on adverse event forms. An analysis was performed to compare the cumulative 
incidence of the first NW angina episodes occurring after index procedure between both groups. This analysis was repeated after excluding 
angina episodes occurring before hospital discharge or <7 days (whichever occurred first). Finally, the total number of angina days per 
treatment group was assessed.
results:  At 1 yr, the cumulative rate of first NW angina was lower in the Absorb group (72 patients [22%]) than in the Xience group (50 
patients [30%], p=0.04). After excluding the angina episodes occurring before hospital discharge or <7 days post- procedure, angina rates 
were also lower in Absorb (54 [16%] vs. 42 [26%], p=0.01) (figure). The total number of angina days was 6,750 in the Absorb group and 
4,437 in the Xience group. The average number of angina days per patient were 20.1 (Absorb) and 26.7 (Xience) in the total population, 
and 105.6 (Absorb) and 122.7 (Xience) for patients having at least one angina episode.
Conclusion:  In the randomized ABSORB II trial, NW angina through adverse event reporting occurred less in Absorb than in Xience. This 
intriguing finding warrants further clinical and physiological investigation.
